News Releases

Date	Title and Summary	View
Dec 30, 2019	Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc. HORSHAM, Pa. , Dec. 30, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) announced today the completion of the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain
Dec 21, 2019	Complete Response Letter Issued from U.S. FDA for Investigational Long-Acting HIV Regimen
Dec 20, 2019	Johnson & Johnson Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer
Dec 20, 2019	Johnson & Johnson Announces Agreement to Acquire Remaining Stake in Verb Surgical Inc.
Dec 19, 2019	Johnson & Johnson to Participate in 38th Annual JP Morgan Health Care Conference NEW BRUNSWICK, N.J. , Dec. 19, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 38 th Annual JP Morgan Health Care Conference on Monday, January 13 , at the Westin St. Francis in San Francisco. Ashley McEvoy , Executive Vice President, Worldwide Chairman, Medical Devices
Dec 19, 2019	SPRAVATO®▼ (Esketamine) Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder
Dec 13, 2019	CHMP Grants Positive Opinion for Expanded Use of Darzalex®▼ (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
Dec 13, 2019	Janssen Receives Positive CHMP Opinion for Expanded Use of Erleada® (apalutamide) for Patients with Metastatic Hormone-Sensitive Prostate Cancer
Dec 10, 2019	Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results NEW BRUNSWICK, N.J. , Dec. 10, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Wednesday, January 22 nd to review fourth-quarter results. Alex Gorsky , Chairman and Chief Executive Officer; Joseph J.
Dec 07, 2019	Janssen to Acquire Investigational Bermekimab from XBiotech